Maehara Osamu 前原経

Researcher Number	80836338
Other IDs
Affiliation (Current)	2025: 北海道大学, 薬学研究院, 助教
Affiliation (based on the past Project Information) *help	2021 – 2023: 北海道大学, 薬学研究院, 助教 2020: 北海道大学, 薬学研究院, 博士研究員
Review Section/Research Field	Principal Investigator Basic Section 53010:Gastroenterology-related Except Principal Investigator Basic Section 53010:Gastroenterology-related
Keywords	Principal Investigator がん幹細胞 / 肝細胞癌 / がん免疫 / 免疫チェックポイント分子 / レンバチニブ / 癌幹細胞 Except Principal Investigator 免疫チェックポイント阻害剤 / 食道扁平上皮癌 / 癌幹細胞

肝細胞癌幹細胞における免疫チェックポイント分子の発現機構の解明Principal Investigator
- Principal Investigator
  
  前原経
- Project Period (FY)
  2023 – 2025
- Research Category
  
  Grant-in-Aid for Early-Career Scientists
- Review Section
  
  Basic Section 53010:Gastroenterology-related
- Research Institution
  Hokkaido University
食道扁平上皮癌がん幹細胞における免疫逃避機構の解明
- Principal Investigator
  
  夏井坂光輝
- Project Period (FY)
  2022 – 2024
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 53010:Gastroenterology-related
- Research Institution
  Hokkaido University
Mechanism of lenvatinib resistance in HCC-CSCsPrincipal Investigator
- Principal Investigator
  
  Maehara Osamu
- Project Period (FY)
  2020 – 2022
- Research Category
  
  Grant-in-Aid for Early-Career Scientists
- Review Section
  
  Basic Section 53010:Gastroenterology-related
- Research Institution
  Hokkaido University

All 2023 2022 2021 2020

All Journal Article Presentation

[Journal Article] Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma2023
- Author(s)
  Yang Zijian、Suda Goki、Maehara Osamu、Ohara Masatsugu、Yoda Tomoka、Sasaki Takashi、Kohya Risako、Yoshida Sonoe、Hosoda Shunichi、Tokuchi Yoshimasa、Kitagataya Takashi、Suzuki Kazuharu、Kawagishi Naoki、Nakai Masato、Sho Takuya、Natsuizaka Mitsuteru、Ogawa Koji、Ohnishi Shunsuke、Sakamoto Naoya
- Journal Title
  
  Cancers
  
  Volume: 15 Issue: 3 Pages: 593-593
- DOI
  10.3390/cancers15030593
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20K08298, KAKENHI-PROJECT-20K17039
[Journal Article] Coexistence of muscle atrophy and high subcutaneous adipose tissue radiodensity predicts poor prognosis in hepatocellular carcinoma2023
- Author(s)
  Ohara Masatsugu、Suda Goki、Kohya Risako、Sasaki Takashi、Yoda Tomoka、Yoshida Sonoe、Fu Qingjie、Yang Zijian、Hosoda Shunichi、Maehara Osamu、Ohnishi Shunsuke、Tokuchi Yoshimasa、Kitagataya Takashi、Kawagishi Naoki、Nakai Masato、Sho Takuya、Natsuizaka Mitsuteru、Ogawa Koji、Sakamoto Naoya
- Journal Title
  
  Frontiers in Nutrition
  
  Volume: 10 Pages: 1-10
- DOI
  10.3389/fnut.2023.1272728
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-22K16008, KAKENHI-PROJECT-23K14998, KAKENHI-PROJECT-23K14999, KAKENHI-PROJECT-22K08023, KAKENHI-PROJECT-22K08046, KAKENHI-PROJECT-21K07953
[Journal Article] Potential Correlation between Changes in Serum FGF21 Levels and Lenvatinib-Induced Appetite Loss in Patients with Unresectable Hepatocellular Carcinoma2023
- Author(s)
  Kohya Risako、Suda Goki、Kawagishi Naoki、et.al.,
- Journal Title
  
  Cancers
  
  Volume: 15 Issue: 12 Pages: 3257-3257
- DOI
  10.3390/cancers15123257
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-23K14998, KAKENHI-PROJECT-23K14999, KAKENHI-PROJECT-22K08023, KAKENHI-PROJECT-21K07953, KAKENHI-PROJECT-23K24311
[Journal Article] Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma2022
- Author(s)
  Yang Zijian、Suda Goki、et al.,
- Journal Title
  
  Cancers
  
  Volume: 14 Issue: 1 Pages: 232-232
- DOI
  10.3390/cancers14010232
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-19K08458, KAKENHI-PROJECT-20K08371, KAKENHI-PROJECT-20K17039, KAKENHI-PROJECT-23K24311
[Journal Article] Low baseline CXCL9 predicts early progressive disease in unresectable HCC with atezolizumab plus bevacizumab treatment2022
- Author(s)
  Hosoda S、Suda G、Sho T、Ogawa K、Kimura M、Yang Z、Yoshida S、Kubo A、Tokuchi Y、Kitagataya T、Maehara O、Ohnishi S、Nakamura A、Yamada R、Ohara M、Kawagishi N、Natsuizaka M、Nakai M、Morikawa K、Furuya K、Baba M、Yamamoto Y、Suzuki K、Izumi T、Meguro T、Terashita K、Ito J、Miyagishima T、Sakamoto N
- Journal Title
  
  Liver Cancer
  
  Volume: - Issue: 2 Pages: 156-170
- DOI
  10.1159/000527759
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20K17039
[Journal Article] Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI2021
- Author(s)
  Kubo Akinori、Suda Goki、Kimura Megumi、Maehara Osamu、Tokuchi Yoshimasa、Kitagataya Takashi、Ohara Masatsugu、Yamada Ren、Shigesawa Taku、Suzuki Kazuharu、Kawagishi Naoki、Nakai Masato、Sho Takuya、Natsuizaka Mitsuteru、Morikawa Kenichi、Ogawa Koji、Ohnishi Shunsuke、Sakamoto Naoya
- Journal Title
  
  Cancers
  
  Volume: 13 Issue: 14 Pages: 3633-3633
- DOI
  10.3390/cancers13143633
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-19K08458, KAKENHI-PROJECT-20K08298, KAKENHI-PROJECT-20K08371, KAKENHI-PROJECT-21K07953, KAKENHI-PROJECT-20K17008, KAKENHI-PROJECT-20K17039
[Journal Article] Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma2021
- Author(s)
  Shigesawa T, Suda G, Kimura M, Maehara O, Tokuchi Y, Kubo A, Yamada R, Furuya K, Baba M, Kitagataya T, Suzuki K, Ohara M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N.
- Journal Title
  
  PLoS One
  
  Volume: 16(3) Issue: 3 Pages: e0247728-e0247728
- DOI
  10.1371/journal.pone.0247728
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20K17008, KAKENHI-PROJECT-20K17039, KAKENHI-PROJECT-19K08458, KAKENHI-PROJECT-20K21592, KAKENHI-PROJECT-19H03630
[Journal Article] FGFR2 maintains cancer cell differentiation via AKT signaling in esophageal squamous cell carcinoma2021
- Author(s)
  Maehara Osamu、Suda Goki、Natsuizaka Mitsuteru、Shigesawa Taku、Kanbe Gouki、Kimura Megumi、Sugiyama Masaya、Mizokami Masashi、Nakai Masato、Sho Takuya、Morikawa Kenichi、Ogawa Koji、Ohashi Shinya、Kagawa Shingo、Kinugasa Hideaki、Naganuma Seiji、Okubo Naoto、Ohnishi Shunsuke、Takeda Hiroshi、Sakamoto Naoya
- Journal Title
  
  Cancer Biology & Therapy
  
  Volume: 22 Issue: 5-6 Pages: 372-380
- DOI
  10.1080/15384047.2021.1939638
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-19K08458, KAKENHI-PROJECT-20K21592, KAKENHI-PROJECT-19H03630, KAKENHI-PROJECT-20K08371, KAKENHI-PROJECT-21K07953, KAKENHI-PROJECT-20K17039
[Journal Article] Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling2020
- Author(s)
  Shigesawa Taku、Morikawa Kenichi et al.
- Journal Title
  
  Carcinogenesis
  
  Volume: 42 Issue: 1 Pages: 58-69
- DOI
  10.1093/carcin/bgaa049
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20K08371, KAKENHI-PROJECT-20K17039, KAKENHI-PROJECT-19H03630
[Presentation] Sequential changes in growth factors during Lenvatinib treatment in patients with unresectable hepatocellular carcinoma2021
- Author(s)
  Yang Z, Suda G, Maehara O, Ogawa K, Kubo A, Toshida S, Tokuchi Y, Kimura M, Kitagataya T, Sho T, Shigesawa T, Yamada R, Nakai M, Morikawa K, Sakamoto N.
- Organizer
  第2回 International Liver Conference
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-20K17039
[Presentation] Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling2020
- Author(s)
  前原経、夏井坂光輝、大西俊介、坂本直哉
- Organizer
  第79回日本癌学会学術総会
- Data Source
  KAKENHI-PROJECT-20K17039

1. 夏井坂光輝 (80642446)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
2. 須田剛生 (20447460)

# of Collaborated Projects: 1 results

# of Collaborated Products: 4 results
3. 坂本直哉

# of Collaborated Projects: 0 results

# of Collaborated Products: 3 results
4. 小川浩司

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
5. 大原正嗣

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
6. 川岸直樹

# of Collaborated Projects: 0 results

# of Collaborated Products: 2 results
7. 森川賢一

# of Collaborated Projects: 0 results

# of Collaborated Products: 3 results

Maehara Osamu 前原 経

Research Projects

Research Products

Co-Researchers

肝細胞癌幹細胞における免疫チェックポイント分子の発現機構の解明Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

食道扁平上皮癌がん幹細胞における免疫逃避機構の解明

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Mechanism of lenvatinib resistance in HCC-CSCsPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

[Journal Article] Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma2023

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Coexistence of muscle atrophy and high subcutaneous adipose tissue radiodensity predicts poor prognosis in hepatocellular carcinoma2023

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Potential Correlation between Changes in Serum FGF21 Levels and Lenvatinib-Induced Appetite Loss in Patients with Unresectable Hepatocellular Carcinoma2023

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma2022

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Low baseline CXCL9 predicts early progressive disease in unresectable HCC with atezolizumab plus bevacizumab treatment2022

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI2021

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma2021

Author(s)

Journal Title

DOI

Data Source

[Journal Article] FGFR2 maintains cancer cell differentiation via AKT signaling in esophageal squamous cell carcinoma2021

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling2020

Author(s)

Journal Title

DOI

Data Source

[Presentation] Sequential changes in growth factors during Lenvatinib treatment in patients with unresectable hepatocellular carcinoma2021

Author(s)

Organizer

Data Source

[Presentation] Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling2020

Author(s)

Organizer

Data Source

Maehara Osamu 前原経